echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Raptor pharmaceutical: cysteamine tartrate recognized by EU orphan drug

    Raptor pharmaceutical: cysteamine tartrate recognized by EU orphan drug

    • Last Update: 2014-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: China Council for the promotion of drugs August 6, 2014 Raptor pharmaceutical company announced that EU has awarded the qualification of cysteamine tartrate orphan drug, the active ingredient of which is rp103, which is used to treat Huntington's disease The decision was made after the Committee on orphan drug products gave a positive opinion in June Christopher Starr, CEO of raptor, said: "this authorization decision is an important milestone in promoting the approval of rp103 for the treatment of Huntington's disease in Europe." Orphan drug qualification allows Raptor to have a 10-year market monopoly in Europe after the drug is approved for marketing 、 http://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.